What is Epipole?
Founded in 2011 by Dr. Craig Robertson, Epipole is an ISO13485 certified medical device company based in Scotland, recognized by the MHRA for its design and manufacturing of retinal imaging devices. Leveraging over 90 years of combined experience in commercial retinal imaging systems, the Epipole team has a proven track record of entrepreneurship, having initiated 10 businesses and developed more than 35 products. The company's expertise lies in vision systems, algorithm development, and mathematical problem-solving, positioning it as a key player in the diagnostic imaging market.
How much funding has Epipole raised?
Epipole has raised a total of $3.6M across 2 funding rounds:
Other Financing Round
$1.9M
Unspecified
$1.7M
Other Financing Round (2020): $1.9M with participation from Greenwood Way Capital Limited
Unspecified (2022): $1.7M led by Scottish Enterprise and Greenwood Way Capital
Key Investors in Epipole
Greenwood Way Capital Limited
Greenwood Way Capital Limited is an investment entity that appears to be involved in providing capital for business development. Their participation suggests a focus on companies with strong growth potential.
Scottish Enterprise
Scottish Enterprise is a national economic development agency dedicated to supporting businesses in Scotland. Their involvement indicates a strategic interest in fostering innovation and growth within the Scottish business landscape, particularly in technology-driven sectors.
Greenwood Way Capital
Greenwood Way Capital is an investment firm that facilitates co-investment opportunities in early-stage companies, often focusing on innovative UK-based businesses with disruptive technologies. Their backing of Epipole suggests alignment with the company's technological advancements and entrepreneurial leadership.
What's next for Epipole?
The recent major strategic investment signals Epipole's readiness for accelerated growth and market penetration. With a strong foundation in regulatory compliance and technological innovation, the company is well-positioned to leverage this capital infusion for scaling its operations, enhancing its product portfolio, and potentially exploring new therapeutic areas or geographical markets. This backing is expected to fuel further research and development, solidifying Epipole's competitive edge in the rapidly evolving medical device industry.
See full Epipole company page
